by Dr. Pierre Eftekhari, CEO of Inoviem Scientific and Bcell Design
Chronic diseases are becoming increasingly prevalent worldwide and show no signs of decline. Across 26 OECD nations, over one-third of adults aged 16 and older reported having a chronic disease or health condition on average. In order to meaningfully deliberate upon the implications of chronic diseases for the pharma industry, it’s important to truly understand the challenges in addressing these chronic diseases.
Firstly, the challenges are multifaceted- safe, effective and affordable treatments that can meet the complex needs of patients have to be developed while also traversing regulatory and financial pressures and barriers in the field.
Read more on Labcompare.